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A B S T R A C T
Background
Cough is the most common symptom which presents to doctors. Chronic cough is reported in up to 9% of preschool aged children.
American general practice guidelines suggest antimicrobial treatment may be indicated in children with cough lasting longer than 10
days. Questions concerning the benefits and harm of antibiotic treatment for prolonged cough in children need to be resolved.
Objectives
A Cochrane systematic review was undertaken to determine the efficacy of antibiotics in treating children with chronic moist cough
(excluding those with bronchiectasis or other underlying respiratory illnesses).
Search methods
The Cochrane Register of Controlled Trials (CENTRAL), the Cochrane Airways Group Specialised Register, MEDLINE, EMBASE,
review articles and reference lists of relevant articles were searched. The latest searches were performed in October 2010.
Selection criteria
All randomised controlled trials (RCTs) comparing antibiotics with a placebo or a control group in children with chronic moist cough
were considered.
Data collection and analysis
Results of searches were reviewed against pre-determined criteria for inclusion. Two independent reviewers selected, extracted and
assessed the data for inclusion. Authors were contacted for further information. Data were analysed as ’intention to treat’.
Main results
Two studies were eligible for inclusion in the review. Neither study was high quality. Both studies failed to include a prospective analysis
of cough quality in their inclusion criteria, although indicating >75% of children included had moist cough (Darelid 1993). A total of
140 patients, aged seven years or less, were included in meta-analysis. Treatment with antibiotics reduced the proportion of children
not cured at follow-up (primary outcome measure) in both studies; pooled odds ratio (OR) was 0.13, 95% CI 0.06 to 0.32 (using
intention to treat analysis), which translates to number needed to treat (NNT) of 3 (95% CI 2 to 4). No significant heterogeneity was
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found (fixed and random-effects model I2 was 4%). However for this outcome measure, the overall estimate of effect and degree of
statistical heterogeneity were sensitive to the model used for meta-analysis. Progression of illness, defined by requirement for further
antibiotics, was significantly lower in the treatment group (OR 0.10, 95%CI 0.03 to 0.34), NNT was 4 (95% CI 3 to 5). Adverse
events were not significantly increased in the treatment group.
Authors’ conclusions
Antibiotics are likely to be beneficial in the treatment of children with chronic moist cough. This evidence is however limited by study
quality, study design and sensitivity analysis data. The use of antibiotics however has to be balanced against their well known adverse
events. Further well-designed RCTs using valid cough outcome measures are needed to answer this question conclusively.
P L A I N L A N G U A G E S U M M A R Y
Antibiotics for prolonged moist cough in children
Cough is the most common symptom which presents to doctors. Some people recommend treating prolonged moist cough with
antibiotics. Two small RCTs were available for analysis although both have methodological flaws. They found that treatment with
antibiotics for prolonged moist cough in children was beneficial with one clinical cure for every three children treated. Antibiotics
resulted in the prevention of illness progression for one in every four patients treated. There were no significant side effects in these
trials. Long-term outcomes were not assessed. This evidence is limited by poor study design and quality. This review supports the use
of antibiotics in children with prolonged wet cough. However further RCTs using better study design, specifically the inclusion and
exclusion factors and validated outcome measures, are required.
B A C K G R O U N D
Cough is the most common symptom which presents to doctors
(Britt 2004). The magnitude of the problem is illustrated by the
amount spent globally on over the counter medications for cough.
In the United Kingdom £92.5 million is spent yearly on cough
syrup. In the United States several billion dollars are spent yearly
on cough and cold pharmaceuticals (Morice 2002). A US sur-
vey showed that 35% of preschool-aged children had used over-
the-counter medications for cough in the previous month (Kogan
1994). A study of primary school aged childrendescribed a lifetime
prevalence of bronchitis of 55.9% (Leonardi 2002). The preva-
lence of chronic cough reported in a large European study was 3%
of school-aged children and 9% in the preschool age group. The
problem was more common in the lower socioeconomic groups
(Spee-van 1998). However, the lack of reliable reporting of cough
limits interpretation of such data (Chang 2001).
The definition of chronic cough in children varies from three
to eight weeks (Chang 2001). As cough due to an acute upper
respiratory tract infection (URTI) is predominantly limited to one
to three weeks duration (Hay 2002), it is arguably logical to define
chronic cough as cough lasting over three weeks. A review of the
natural history of acute cough found that 5-10% of preschool
aged children still cough at three weeks and these children have
’complicated’ upper respiratory tract infections (Hay 2002). In
this review, prolonged cough is defined as cough lasting longer
than 10 days.
Wet/moist and dry cough can be clinically well differentiated by
clinicians and parents (Chang 2005). A dry cough in the absence
of identifiable respiratory disease (i.e. absence of other symptoms
and signs) or known aetiology is also termed non-specific cough
(Chang 2003). Children with non-specific cough do not have
any of the pointers associated with specific cough (Chang 2001).
Chronic cough that is moist-sounding or productive is referred
to as specific cough because the increased production of airway
secretions reflects a degree of primary pulmonary pathology.
The role of antibiotics in chronic or prolonged cough is unclear.
Antibiotics provide a modest benefit in the treatment of acute
bronchitis (Fahey 2004) and have no efficacy in treatment of the
common cold (Arroll 2005). In children with prolonged cough,
the American Pediatric URI Consensus Team surmised that “an-
timicrobial treatment for prolonged cough (longer than 10 days)
may be indicated occasionally” (Dowell 1998). Despite these con-
servative recommendations, antibiotics are oftenprescribed.Ques-
tions concerning the benefits and harm of antibiotic treatment in
these circumstances need to be resolved.
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O B J E C T I V E S
To determine the efficacy of antibiotics in treating children with
prolonged moist cough (excluding children with bronchiectasis or
other underlying respiratory illness).
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials comparing antibiotics with a
placebo medication or ’no treatment’ control group.
Types of participants
All trials which included children under 18 years of age with pro-
longedmoist cough (longer than 10 days). A priori subgroup anal-
yses were planned for children under seven years of age and cough
lasting over three weeks). Exclusion criteria: radiological evidence
of bronchiectasis or lung histopathological evidence of bronchiec-
tasis, diagnosis of cystic fibrosis, cough related toMycoplasma pneu-
moniae, B.pertussis and Chlamydia, presence of underlying cardio-
respiratory condition (haemoptysis, recurrent pneumonia, chronic
dyspnoea), current or recurrent wheeze (over two episodes), pres-
ence of the respiratory signs of clubbing or wheeze on ausculta-
tion, presence of any sign of systemic illness (failure to thrive, aspi-
ration, neurological or developmental abnormality and immune
deficiencies).
Types of interventions
All randomised controlled comparisons of antibiotics versus
placebo or control group in the management of prolonged moist
cough. Antibiotics could be given via any route. Trials only com-
paring two or more antibiotics without a placebo were not in-
cluded.
It was planned that three separate treatment regimes would be
evaluated:
i) Short term treatment (seven days or less)
ii) Long term antibiotics (more than seven days)
iii) Intravenous antibiotic treatment where antibiotics were given
intravenously for at least five days
Trials that included the use of other medications or interventions
were included if all participants had equal access to such medica-
tions or interventions or if the additional therapies were regarded
as ineffective.
Types of outcome measures
Attempts were made to obtain data on at least one of the following
outcome measures:
Primary outcomes
Proportions of participantswhowere not cured or not substantially
improved at follow up (clinical failure).
The proportions of participants who failed to improve on treat-
ment and the mean clinical improvement were determined using
the following hierarchy of assessment measures (i.e. where two or
more assessment measures were reported in the same study, the
outcome measure that is listed first in the hierarchy was used).
i) Objective measurements of cough indices (cough frequency,
cough receptor sensitivity, cough amplitude).
ii) Symptomatic (Likert scale, visual analogue scale, level of inter-
ference of cough, cough diary, sputum production - quantity and
colour, general well-being) - assessed by the child.
iii) Symptomatic (Likert scale, visual analogue scale, level of inter-
ference of cough, cough diary, sputum production - quantity and
colour, general well-being) - assessed by the parents/carers.
iv) Symptomatic (Likert scale, visual analogue scale, level of inter-
ference of cough, cough diary, sputum production - quantity and
colour, general well-being) - assessed by clinicians.
v) Airway markers (sputum or BAL) consistent with infection or
inflammation.
vi) Sputum volume alone.
vii) Lung function tests alone.
Secondary outcomes
a) Mean difference in symptoms (mean improvement in clinical
state);
b) Mean difference in sputum, bronchoalveolar lavage (BAL) or
blood indices of inflammation or infection (mean improvement
in markers of infection);
c)Meandifference in cough indices (cough diary, cough frequency,
cough scores),
d) Proportions of participants with progression of the disease re-
sulting in additional medical therapy (complications);
e) Proportions experiencing adverse effects of antibiotics e.g. diar-
rhoea, nausea, skin rash, allergic reactions (side effects).
For studies where data was not available on any of the pre-specified
outcome measures but the study was eligible for inclusion it was
planned to described the outcome measures in the ’Characteristics
of the included studies’ table. However these studies would not
have been included in the meta-analyses.
Search methods for identification of studies
3Antibiotics for prolonged moist cough in children (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
The following topic search strategy was used to identify relevant
randomised controlled trials. The full database strategies are shown
in Appendix 1.
(cough [MeSH] OR cough* [text word] OR bronchitis [MeSH]
OR bronchit* [text word]) AND
(Anti-bacterial Agents [MeSH] OR antibiot* or anti-biot* or an-
timicrob* or anti-microb* or antibacterial* or anti-bacterial* [text
words]) AND
(child [MeSH] OR adolescent [MeSH] OR infant[MeSH] OR
Pediatrics[MeSH] OR child* or paediat* or pediat* or adolesc* or
infan* or toddler* or bab* or young* or preschool* or pre school*
or pre-school* or newborn* or new born* or new-born* or neo-
nat* or neonat* [text words])
Trials were identified from the following sources:
1. The Cochrane Controlled Trials Register (CENTRAL), Issue 3
2010, which includes the Airways Group Specialised Register.
2. MEDLINE 1966-October 2010.
3. OLDMEDLINE 1951-1965.
4. EMBASE 1997-October 2010.
5. The list of references in relevant publications.
6. Written communication with the authors of trials included in
the review, if required.
Data collection and analysis
Retrieval of studies: From the title, abstract, or descriptors, two
reviewers (JM, JG) independently reviewed literature searches and
identified potentially relevant trials for full review. Searches of bib-
liographies and texts were also conducted to identify additional
studies. Using specific criteria, the same two reviewers indepen-
dently selected trials for inclusion in the review. It was planned
that disagreement would be resolved by third party adjudication
(AC).
Trials that satisfied the inclusion criteria were reviewed indepen-
dently by two reviewers (JM, AC). The following information was
recorded: study setting, year of study, source of funding, patient
recruitment details (including number of eligible children), in-
clusion and exclusion criteria, randomisation and allocation con-
cealment method, numbers of participants randomised, blind-
ing (masking) of participants, care providers and outcome asses-
sors, dose and type of antibiotic therapy, duration of therapy, co-
interventions, numbers of patients not followed up, reasons for
withdrawals from study protocol (clinical, side-effects, refusal and
other), details on side-effects of therapy, and whether intention-
to-treat analyses were possible. Data were extracted on the out-
comes described previously by two reviewers (JM, AC) and double
entry of data for meta-analysis was used. Further information was
requested from the authors of both studies.
1. Studies included in the review were independently assessed
for quality by two reviewers. Four components of quality were
assessed:
2. Allocation concealment. Trials were scored as: Grade A:
Adequate concealment, Grade B: Unclear, Grade C: Clearly
inadequate concealment. (Grade A = high quality).
3. Blinding. Trials were scored as: Grade A: Participant and
care provider and outcome assessor blinded, Grade B: Outcome
assessor blinded, Grade C: Unclear, Grade D: No blinding of
outcome assessor (Grade A, B = high quality).
4. Reporting of participants by allocated group. Trials were
scored as: Grade A: The progress of all randomised children in
each group described, Grade B: Unclear or no mention of
withdrawals or dropouts, Grade C: The progress of all
randomised children in each group clearly not described. (Grade
A = high quality).
5. Follow-up. Trials were scored as: Grade A: Outcomes
measured in >90% (where withdrawals due to complications and
side-effects are categorised as treatment failures), Grade B:
Outcomes measured in 80-90%, Grade C: Unclear, Grade D:
Outcomes measured in <80%. (Grade A = high quality).
While only the allocation concealment quality assessment are dis-
played in the meta-analysis figures, all assessments have been in-
cluded in the ’Characteristics of included studies’ table. Inter-re-
viewer reliability for the identification of high quality studies for
each component was measured by the Kappa statistic.
Each study was also assessed using a 5-point scale described by
Jadad et al (Jadad 1996) and summarised as follows:
Was the study described as randomised? (1=yes; 0=no)
Was the study described as double blind? (1=yes; 0=no)
Was there a description of withdrawals and dropouts? (1=yes; 0=
no)
Was the method of randomisation clearly described and appropri-
ate? (1=yes; 0=no)
Was the method of double blinding well described and appropri-
ate? (1=yes; 0=no)
Statistics
For the dichotomous outcome variables of each individual study,
odds ratios were calculated using a modified intention to treat
analysis. This analysis assumes that children not available for out-
come assessment have not improved (and probably represents a
conservative estimate of effect). An initial qualitative comparison
of all the individually analysed studies examined whether pooling
of results (meta-analysis) was reasonable. This took into account
differences in study populations, inclusion/exclusion criteria, in-
terventions, outcome assessment, and estimated effect size.
The results from studies that met the inclusion criteria and re-
ported any of the outcomes of interest were included in the sub-
sequent meta-analyses. The summary weighted odds ratio and
95% confidence interval (fixed-effects model) were calculated us-
ing the inverse of the variance of each study result for weighting
(Cochrane statistical package, RevMan 4.2). Number needed to
treat (NNT) was calculated from the pooled OR and its 95% CI
applied to a specified baseline risk using an online calculator (Cates
2003). This calculator converts the risk in the placebo group to
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the corresponding odds, applies the OR to estimate the odds in
the treated group, and converts that odds to the corresponding
risk and calculates the risk difference, the inverse of which is the
NNT. The cough indices were assumed to be normally distributed
continuous variables so the mean difference in outcomes was es-
timated (weighted mean difference). If studies reported outcomes
using different measurement scales, the standardised mean differ-
ence was estimated. Any heterogeneity between the study results
was described and tested to see if it reached statistical significance
using a chi-squared test. The 95% confidence interval estimated
using a random-effects model was included whenever there were
concerns about statistical heterogeneity.
An a priori subgroup analysis was planned for children less than
seven years of age. Sensitivity analyses were planned to assess the




c) variation in the inclusion criteria;
d) differences in the medications used in the intervention and
comparison groups;
e) differences in outcome measures;
f ) analysis by ’intention to treat’ but only including participants
not lost to follow-up (available data analysis);
g) analysis by ’treatment received’ rather than ’intention to treat’
and
h) model used (RR versus OR)
It was planned that publication bias be tested by use of a funnel
plot.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
The Airways Group register/search identified 2779 potentially rel-
evant titles (see Appendix 2 for search history). After assessment
of the abstracts, 13 papers were obtained for consideration for
inclusion into the review. Two studies were included in the final
review. The main reason studies were excluded was acute cough
rather then chronic (five studies - see table of excluded studies).
Other reasons included lack of randomisation and retrospective
review articles. There were no studies which used oral antibiotic
therapy for over seven days or intravenous therapy in children.
The two studies included were single-centred studies and neither
received support from commercial interests. Both studies were
conducted in the setting of a paediatric outpatient clinic in Sweden
and both recruited children with over 10 days of cough. Around
50% of patients had cough of greater than three weeks duration
in one study (Darelid 1993) and the mean length of cough was
three to four weeks in the other (Gottfarb 1994). The median age
of participants in Darelid’s study was not provided but 63% of
the patients were aged one to three years (Darelid 1993). Median
age of children in Gottfarb’s study was 2.6 years (Gottfarb 1994).
The study populations appeared very similar. Although the quality
of cough was not specifically outlined in either study, it is likely
that the majority of children recruited had a moist cough as both
studies included nasopharyngeal aspirates which grew a range of
bacterial pathogens. Indeed, contact with trialists confirmed this
as Dr Darelid estimated that >75% of participants in his trial had
a moist cough (Darelid 1993).
Both studies used short term antibiotic therapy (seven days). Both
used paediatrician assessment of clinical recovery as primary out-
come measure but the day of assessment was different (day eight
(Darelid 1993) and day 12-14 (Gottfarb 1994)). The exclusion
criteria of both studies included pneumonia, suspected B.pertussis
infection and otitis media. The study by Darelid (Darelid 1993)
also excluded children with allergy, asthma, cardiac disease and
tonsillitis. This more comprehensive exclusion criteria provides a
clearer definition of patients enrolled in the study and is a limi-
tation of the other study. Neither study makes specific mention
of the exclusion of patients with cystic fibrosis or bronchiectasis
although it is assumed this is the case.
Darelid et al’s study (Darelid 1993) was an open randomised study
comparing erythromycin and a no treatment control group. Gott-
farb and colleagues (Gottfarb 1994) compared amoxicillin/clavu-
lanic acid and placebo in a double-blinded randomised controlled
study. Darelid (Darelid 1993) used a dosage regime of 50 mg/
kg/day which is equal to current recommended treatment dosage.
The dosage in Gottfarb’s study was lower (dosage 20 mg/kg/day)
(Gottfarb 1994) then currently recommended doses (22.5 to 45
mg/kg/day) (Kemp 1997). Although different antibiotics were
used in the studies, both would treat the respiratory pathogens
found in the nasopharyngeal aspirates of these patients and organ-
isms in bronchoalveolar lavage in other studies on chronic cough
in children (Marchant JM2003).One study allowed the use of oral
salbutamol mixture in both groups and this was recorded (Darelid
1993). All the children in this study received oxymetazoline nose
drops. Neither of these treatments should have influenced the out-
come given they were available to both groups. No co-interven-
tions were allowed in the second trial (Gottfarb 1994). Neither
trial reported appropriately on compliance measures for patients
although Darelid et al (Darelid 1993) reported 97% of patients
completed the erythromycin medication. The trialists failed to
state how this was assessed.
Outcomes were assessed at day eight (Darelid 1993) and day 12
to 14 (Gottfarb 1994) respectively, so only short-term effects were
described by the results. The primary outcome measure in both
studies was paediatrician assessment of clinical outcome at follow-
up. Patients were classified as cured or treatment failure. Both stud-
ies also reported parental assessment and used individual symp-
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tom scores as secondary outcome measures. Side effects and pro-
gression of disease requiring further antibiotic therapy was also
documented. Darelid and colleagues (Darelid 1993) also recorded
and documented the elimination of nasopharyngeal pathogens in
the intervention and control groups. Gottfarb’s (Gottfarb 1994)
study excluded 15 children from the final analysis without indi-
cating which treatment group they were initially allocated to. As
contact with the authors was unsuccessful, we assumed that there
were equal numbers of children in each group in the intention to
treat analysis. Of the 15 children excluded 12 had laboratory con-
firmed Bordetella pertussis after randomisation which is a potential
weakness of the study. Ideally the diagnosis of B.pertussis would
have been made prior to randomisation and then these children
would not have been eligible to enter the study.
Risk of bias in included studies
Darelid’s study (Darelid 1993) had a Jadad score of two and that
of Gottfarb (Gottfarb 1994) was three. The Jadad scores are con-
sistent with the assessment of the individual components of the
RCT quality. The study by Darelid (Darelid 1993) was high qual-
ity in terms of follow-up and reporting but poor quality for al-
location concealment and blinding (open randomised study with
’no treatment’ control group). The study by Gottfarb scored high
in blinding measures only. Although both studies are randomised
neither described the method of randomisation clearly. Although
the study byGottfarb and colleagues (Gottfarb 1994)was a double
blind study it does not report how this was achieved. No mention
of allocation concealment was made in either paper. The study by
Darelid had only one withdrawal which is adequately described.
The second study (Gottfarb 1994) had 15 patients who were with-
drawn from the study. Although they mentioned the reasons for
withdrawal, they failed to indicate which groups they have come
from. A risk of bias assessment has been made for both studies (see
’Characteristics of included studies’). The agreement between the
two reviewers (JM, AC) was good (weighted kappa score for Jadad
scale was 1.0 and for quality assessment scores was 0.74).
Effects of interventions
The two studies included a total of 140 children. Sixteen patients
were lost to follow-up or withdrew from the trial for other reasons,
such as Bordetella pertussis infection. Both studies used short term
antibiotic therapy of seven days.
Primary outcome:
a) Proportions of participants who were not cured or not substan-
tially improved at follow-up (clinical failure).
Data from both studies were combined for this outcome measure.
The number of patients not cured at follow-up was 76 using in-
tention to treat analysis. The control event rate was 64% (Darelid
1993) and 88% (Gottfarb 1994) in the two studies. Treatment
with antibiotics reduced the proportion of children not cured at
follow-up in both studies; the pooled OR effect estimate was 0.13
(95% CI 0.06 to 0.32). These studies suggest that one child will
be cured for every three children treated (NNT = 3, 95%CI 2 to
4) (Figure 1). However the overall estimate of effect and degree of
statistical heterogeneity were sensitive to the model used for meta-
analysis (see sensitivity analysis). The subgroup data for children
with prolonged moist cough for over three weeks were not avail-
able. All patients were aged seven years or less, so subgroup analysis
could not be performed. The long-term effects of antibiotics were
not assessed.
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Figure 1. Children not cured or substantially improved at follow-up
Secondary outcomes:
b) Mean difference in symptoms (mean improvement in clinical
state)
Neither study looked at symptoms individually.
c) Mean difference in sputum, bronchoalveolar lavage (BAL) or
blood indices of inflammation or infection (mean improvement
in markers of infection)
No analysis of sputum, BAL or blood indices of infection were
described. The study by Darelid (Darelid 1993) examined clear-
ance of potential pathogens from the nasopharynx. It found a sig-
nificant elimination of Moraxella catarrhalis from the nasophar-
ynx in treated (68%) versus untreated patients (20%, P<0.001).
Similar results were found for Streptococcus pneumoniae (treated
elimination 100%; untreated 23%; P<0.0001). They also found
a correlation with growth of Moraxella catarrhalis and persistent
cough after the trial. In the untreated group, 80% of those with
untreatedMoraxella catarrhalis continued to cough versus 33% of
those with no growth of this organism (P<0.01).
d)Meandifference in cough indices (cough diary, cough frequency,
cough scores)
These measures could not be combined due to the differing nature
of the indices. Darelid and colleagues (Darelid 1993) used a score
which combined cough frequency, morning temperature and level
of daily activity whereas Gottfarb and colleagues (Gottfarb 1994)
looked at the number of coughing attacks in a 24 hour period.
e) Proportions of participants with progression of the disease re-
sulting in additional medical therapy (complications)
Despite the differences in study design the proportion of patients
with progression of disease can be combined using an ’intention
to treatment’ analysis of available data. Overall there were 125
children who contributed data on this outcome (excluding the
15 drop-outs in Gottfarb’s study (Gottfarb 1994)). The overall
control event rate for complications was 36% versus a treatment
event rate of 5%. Progression of illness, as defined by requirement
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for further antibiotics in both papers, was significantly lower in
the treatment group (pooled OR 0.10, 95%CI 0.03 to 0.34). The
number needed to treat to avoid progression of disease was four
(NNT = 4, 95%CI 3 to 5).
f ) Proportions experiencing adverse effects of antibiotics e.g. diar-
rhoea, nausea, skin rash, allergic reactions (side effects)
In Darelid’s study, children in the erythromycin group had a re-
ported side effect rate of 2% (Darelid 1993). The side effects noted
were diarrhoea and vomiting. It can be argued that these results
should not been pooled as one study (Darelid 1993) used a control
group and therefore did not report any side effects for this popu-
lation. The rate of side effects in the study comparing amoxicillin/
clavulanic acid and placebo was 12% for both treatment and con-
trol groups (Gottfarb 1994). Pooling the results, assuming that
no one in the control (no treatment) group in Darelid’s (Darelid
1993) had any adverse events, there was no significant difference
between the groups; OR 1.38 (95%CI 0.31, 6.08).
Sensitivity Analyses
As there were only two studies in this review, reanalysis by study
quality, size, differences in the medications used was not possible.
When the analysis was performed using analysis by ’intention to
treat’ but only including participants not lost to follow-up (avail-
able data analysis) the primary outcome did not change; effect
estimate 0.12 versus 0.13. Assessing the data by excluding those
with proven Bordetella pertussis infection (Gottfarb 1994) did not
change the OR from 0.13. Neither the analysis of available data
only or of Gottfarb’s study without the Bordetella pertussis patients
(Gottfarb 1994) altered the number needed to treat. There was no
difference when a random-effects model was used versus a fixed-
effects model; OR for primary outcome 0.13 (fixed) versus 0.13
(random). Both the Chi2 and I2 statistical tools show low level of
heterogeneity between the two studies, with I2 =3.7% and Chi2 =
1.04 for the primary outcome measure.
In the primary outcome (clinical failure) the overall estimate of
effect and degree of statistical heterogeneity were sensitive to the
model used for meta-analysis (pooled RR 0.46, 95%CI 0.32 to
0.65 (fixed-effects model, I2 92%); pooled RR 0.43, 95%CI 0.1
to 1.8 (random-effects model, I2 92%). However the heterogene-
ity disappeared (using fixed model, I2 0%) and pooled RR again
favoured treatment 2.46 (95%CI 1.67, 3.64) when clinical suc-
cess rather than clinical failure was used as the outcome measure.
The ’proportions of participants with progression of the disease
resulting in additional medical therapy’ did not change substan-
tially with the use of relative risks rather than odds ratios (from
pooled OR of 0.10, 95%CI 0.03 to 0.34 (random-effects model)
to pooled RR 0.15, 95%CI 0.05 to 0.49 (random-effects model)).
In both models (OR or RR), there was no significant heterogene-
ity. Both results significantly favoured use of antibiotics to prevent
progression of disease. Based on these results ORs (rather than
RRs) were used throughout this review.
D I S C U S S I O N
Thismeta-analysis has suggested that antibiotics are effective treat-
ment in children with a chronic moist cough, both in outcomes of
’clinical cure’ and ’illness progression’ (reduction in proportions
of children subsequently requiring antibiotics). The data available
indicate that in the population of children seven years or younger,
with chronic cough three childrenwill need to be treated to achieve
one clinical cure. This supports the current American Pediatric
URI Consensus Team statement that “antimicrobial treatment for
prolonged cough (longer than 10 days) may be indicated occasion-
ally” (Dowell 1998). These findings specific for prolonged cough
differs from other reviews on antibiotics which showed that an-
tibiotics have only minimal benefit (if any) in the treatment of
acute bronchitis (Fahey 2004) and have no efficacy in treatment
of the common cold (Arroll 2005).
In paediatrics, chronic cough is usually defined as cough duration
of over three weeks. Ideally this review would include children
with cough lasting over three weeks but there were no such studies.
Both studies (Darelid 1993; Gottfarb 1994) used over 10 days of
cough as the definition of prolonged cough. Certainly this would
be classified as subacute cough in the available paediatric literature
(Chang 2001). A percentage of the children with cough will cease
spontaneous before 3 weeks (Hay 2002). Neither of the authors of
the included studies were able to separate those with cough for 10-
21 days versus those with over 21 days cough although both studies
had a large percentage of childrenwith cough over threeweeks. The
decision to include these studieswhich enrolled some childrenwith
shorter duration cough was made because although spontaneous
resolution may occur in some patients it should occur equally in
both treatment and placebo groups. Therefore is unlikely to alter
the review outcome favourably but may limit the strength of it.
Neither study enrolled children with the particular cough char-
acteristic of wet cough. A recent study has shown that the cough
quality of wet vs dry cough can be validly used (Chang 2005).
On correspondence with Darelid (Darelid 1993), he reported that
>75% of patients in his study had moist cough. Given the stud-
ies were carried out in the same geographical area and in similar
patient group one could assume that the second study (Gottfarb
1994) had a similar proportionof childrenwithmoist cough. Since
a chronic moist cough in this patient age group is more likely to be
a bacterial bronchitis then any other cause (Marchant JM 2004)
(and this should respond to antibiotic therapy) including children
with dry cough would decrease any effect.
Children presenting with chronic moist cough are likely to have a
different disease to those with acute bronchitis or common cold.
A number of studies have evaluated airway inflammation in chil-
dren with chronic cough and shown that they have a different pat-
tern of airway inflammation to atopic children who present with
asthma or to controls (Fitch 2000; Gibson 2001; Marchant JM
2003). These studies have shown that on bronchoalveolar lavage
8Antibiotics for prolonged moist cough in children (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
the percentage of inflammatory cells in the airway, particularly
neutrophils, were higher then expected normal values. One study
has shown that protracted bacterial bronchitis is common in chil-
dren with chronic (over three weeks) cough (Marchant JM 2004).
This may explain the findings of this review that antibiotics appear
to be beneficial for prolonged moist cough in children.
The pooled adverse events described in the two eligible studies
showed no difference between the groups. The percentage of pa-
tients with side effects was low in both studies, being 2% in the
study by Darelid for treatment group (Darelid 1993) and in Got-
tfarb’s study (Gottfarb 1994) side effects were similar in both
groups. In considering the trade-offs of antibiotic therapy one
must remember that a small number of children will have adverse
events as a result of the therapy (insufficient data to calculate num-
ber needed to harm). A further factor must be considered in the
benefit versus harm debate and that is participants with progres-
sion of disease resulting in additionalmedical therapy (antibiotics).
The control event rate was 36% (versus 5% in treated group) and
the OR 0.10 significantly favouring treatment to decrease the in-
cidence of complications for children with chronic wet cough.
Both studies (Darelid 1993, Gottfarb 1994) used physician as-
sessed ’clinical cure’ as the outcome measure but these were un-
defined. Neither study assessed adequately differences in cough
symptoms or used appropriate cough indices such as a cough diary
or cough frequency. Therefore these measures have not been com-
bined inmeta-analysis. A previously validated cough diary (such as
the verbal category descriptive (VCD) score for daytime and noc-
turnal cough (Chang 1998)) would have been helpful. It would
have allowed patient data on cure, or otherwise, to be evaluated
(rather than simply physician diagnosis of clinical cure). One ex-
cluded study (for an inadequate control group) (Yun 1983) did ap-
propriately and accurately define ’clinical cure’ as no cough present
after 14 days of therapy. This study showed a significant benefit
for antibiotics in keeping with our meta-analysis results with a
significant difference between the antibiotic (treatment event rate
for cure 46%) and expectorant/decongestant group (control cure
event rate 14%) (p<0.001) but was unable to be included in the
meta-analysis as it did not meet inclusion criteria.
Although neither study assessed specifically differences in sputum,
bronchoalveolar lavage or blood indices of inflammation and in-
fection the paper by Darelid (Darelid 1993) looked at the organ-
isms grown on nasopharyngeal aspirate and the clearance of these
post-treatment. It showed a significant elimination of Moraxella
catarrhalis from the nasopharynx of treated patients. The presence
of this organism in bronchoalveolar lavage of childrenwith chronic
bacterial bronchitis who presented with chronic cough has been
recently found, along with predominantly Streptococcus pneumo-
niae andHaemophilus influenzae (Marchant JM2004). The organ-
isms found on bronchoalveolar lavage in this patient population
are vital when considering appropriate antibiotic therapy. The two
studies have chosen different antibiotics, erythromycin (dosage
of 50 mg/kg/day) (Darelid 1993) and amoxicillin/clavulanic acid
(dosage 20 mg/kg/day) (Gottfarb 1994). Darelid’s study (Darelid
1993) trialed erythromycin, a macrolide antibiotic, which has tra-
ditionally covered the common pathogens found in the lower res-
piratory tract such as Streptococcus pneumoniae and Haemophilus
influenzae (as well as the atypical pathogens such as Mycoplasma
species) (Alvarez-Elcoro 1999). Increasing emergence ofmacrolide
resistance to the common pathogens may limit their usefulness in
the future as illustrated by a recent study which found 13.7% of
Streptococcus pneumoniae in school-aged children were resistant to
erythromycin (Gazi 2004). In contrast Gottfarb used Augmentin
(amoxicillin/clavulanic acid) an antibiotic with broad coverage of
the organisms likely to be found on bronchoalveolar lavage in chil-
dren with chronic wet cough, namely Streptococcus pneumoniae,
Haemophilus influenzae and Moraxella catarrhalis (Marchant JM
2004). In the study byGazi (Gazi 2004) only 1.2%ofHaemophilus
influenzaewere resistant to amoxicillin/clavulanic acid and none of
theMoraxella catarrhalis or Streptococcus pneumoniae. Gottfarb has
chosen a very low dosage schedule (20 mg/kg/day) compared with
standard practice (45 mg/kg/day) which may limit the efficacy of
the drug and so rate of clinical cure in the trial (Kemp 1997). The
ideal RCT would trial appropriate antibiotic therapy used at an
appropriate dosage to treat the organisms predominantly found
on bronchoalveolar lavage in children.
Limitations of review
This systematic review is limited to two small studies of poor qual-
ity with limited availability of data for analysis. Some assump-
tions about the data were made for both studies (cough quality
and equal dropouts in intervention and control groups). Neither
of the studies scored highly on the Jadad quality scale or the in-
dividual assessment of each important quality component. The
review is also limited by lack of inclusion of validated objective
measures of cough, such as the verbal category descriptive cough
diary (Chang 1998). The lack of data on quality of cough allows
the possibility of greater clinical heterogeneity of participants then
one would anticipate. The failure to state exclusion of children
with cystic fibrosis, bronchiectasis and other underlying lung dis-
ease, although implied, is another flaw of both studies which needs
to be addressed in subsequent RCTs. Inclusion of children with
these disease states may influence the results of this meta-analysis.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Whenconsidering implications for practice of this reviewonemust
remember the data is based on two small studies with method-
ological flaws. Clearly further high-quality studies are needed be-
fore this evidence can be accepted as conclusive. Acknowledging
this the available evidence suggests that antibiotics are efficacious
in young children, aged seven years or less, with prolonged wet
cough with three or four patients cured for every 10 treated. The
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use of antibiotics in children with prolonged wet cough is also
associated with a reduction in the progression of illness whereby
children on antibiotics are less likely to require further antibiotics
for treatment of complications. One must remember antibiotics
are not without side effects when considering this treatment op-
tion. The conclusions of this review are applicable only to children
with persistent wet cough whichmust be differentiated from acute
cough where the role of antibiotics is clearly very different and has
been addressed in other reviews.
Implications for research
Well designed RCTs which use appropriate randomisation, dou-
ble-blinding and allocation concealment are required to assess the
role of antibiotics in chronic moist cough in children. The trials
should include children with cough of > 3 weeks to assess only
those with chronic cough, and so avoid the natural resolution that
can occur in the first three weeks. The addition of cough quality
(wet cough only) to the inclusion criteria for participants will de-
crease the clinical heterogeneity within the subjects. It is impor-
tant that future RCTs exclude children with bronchiectasis, cys-
tic fibrosis and underlying chronic lung disease and cough related
to B.pertussis or Mycoplasma pneumoniae. Children with specific
cough such as wheeze on auscultation should also be excluded as
these may indicate other underlying pathology and again broad-
ens the heterogeneity of the trial participants (possibly decreas-
ing the efficacy of the antibiotic treatment). The design of future
RCTs should include objective measures of cough outcomes such
as cough frequency or validated symptomatic measures such as
cough diary or visual analogue scale as assessed by the child (if age
permits) or the parent/carers. A clear and appropriate definition
of clinical cure should be included in the trial design. Secondary
measures such as differences in sputum, bronchoalveolar lavage
or blood indices of inflammation or infection will also strengthen
future trial outcomes. Future RCTs should incorporate sufficient
longitudinal follow-up of these patients to assess the longevity of
clinical cure in these patients.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Darelid 1993
Methods Open randomised study comparing erythromycin and no treatment (as control group).
At baseline patients had a history and clinical examination performed. A nasopharyngeal
swab was obtained at baseline and again 18-36 hours after last antibiotic dose. A repeat
doctors examination was performed on Day 8
Randomisationwas open and done by a computer-generated table.No other information
given about randomisation. Allocation concealment was not done (gradeC).Not blinded
due to open design of study (quality assessment grade D). Compliance monitoring not
described
Dropouts: n=1 (1.1% of patients randomised) from treatment group from adverse effects
of antibiotics. No further description given and was not included in analysis as treat-
ment failures. Quality assessment of reporting of participants and follow-up of patients
therefore were of a high quality (A)
Participants 88 children with cough >10 days duration were included. The number of participants
with cough > 3 weeks duration was 50%. Approximately 75% of the participants had
moist cough.
Erthromycin group: n=41 Control group n=47 . There were no significant differences
in any patient characteristics between the 2 groups
Inclusion criteria: Children aged 0.5 - 6 years attending one of 3 paediatric outpatient
clinics with greater than 10 days of cough
Exclusion criteria: Children with allergy, asthma, cardiac disease, otitis media, tonsillitis,
pneumonia or clinically suspected pertussis
Interventions Treatment group received erythromycin ethylsuccinate suspension 50mg/kg/day in 2
divided doses for 7 days verus ’no treatment’ control group. All children received nose
drops (oxymetazoline chloride). Salbutamolmixture (0.1mg/kg/day) was allowed in both
groups and was registered
Outcomes 1. Clinical symptoms as recorded on a questionnaire by parents, including cough on 3
point scale (none,moderate or frequent), morning temperature and degree of activity of
child (usual, reduced, bedridden).
2. Doctor performed clinical examination on Day 8 to assess cure or clinical failure
(without knowledge of questionnaires).
3. Elimination of nasopharyngeal pathogens
4. Progression of disease requiring additional antibiotics (% complications) ie bacterial
complications requiring further antibiotics and recurrent symptoms were recorded dur-
ing therapy and for 3 months after.
5. Adverse drug reactions
Notes 4 children in each arm had received antibiotic treatment prior to enrolment for <30 days
Quality Score: CDAA
Risk of bias
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Darelid 1993 (Continued)
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Computer-generated table
Allocation concealment? High risk Open
Blinding?
All outcomes
High risk Open study
Incomplete outcome data addressed?
All outcomes
Low risk Only one patient withdrew from the study.
Gottfarb 1994
Methods Randomised double blind study comparing Amoxycillin/clavulanic acid vs placebo. At
baseline clinical data was obtained and participants underwent nasopharyngeal aspirate
and blood tests for B.pertussis and Mycoplasma pneumoniae. A cough scoring system
which combined number of coughing attacks per 24 hours, coughing attacks associated
with vomiting and wheeze or crackles on auscultation was obtained. At 2 weeks partici-
pants were followed-up with repeat blood tests, nasopharyngeal aspirates and doctor as-
sessment of clinical outcome. Parental assessment of treatment efficacy was also recorded.
Number of coughing attacks per 24 hours was recorded for each day of treatment
Randomisation method was not described. Allocation method was not described. Com-
pliance monitoring was not described. Although a double-blinded study there was no
mention of how this was achieved in the paper
Dropouts n=15 (26.3% of those recruited). 12 with pertussis, 2 failed to return to follow-
up visit, 1 refused medication. These were not further described and not included as
treatment failures in the paper
Participants 52 children with cough >10 days duration were included. The mean duration of cough
was 3-4 weeks. Number with moist cough was not reported.
Median age of groups: Amoxycillin/clavulanic acid 2.7 years; Placebo 2.6 years (Num-
bers in each group not described).There was no significant differences in any patient
characteristics between the two groups
Inclusion criteria: Children aged 0.6-7 years with > 10 days of cough and > 7 points on
cough score system
Exclusion criteria: Children with any signs of pneumonia, acute otitis media or clinical
suspicion of Bordetella pertussis infection
Interventions Treatment group received amoxycillin/clavulanic acid 20mg/kg/day for 7 days verus
placebo group.
The children were not given any antitussive medication.
Outcomes 1. Paediatrician’s assessment of clinical recovery on day 12-14.
2. Parental assessment of recovery on Day 12-14.
3. Number of coughing attacks each day of treatment recorded until day 8
4. Adverse events
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Gottfarb 1994 (Continued)
Notes Due to lack of information in the paper and an inability to obtain data from authors
about the dropouts with pertussis, it was assumed that there were equal numbers of
patients in each treatment group analysed. (37 patients became 18 each group)
Quality Score: BACD
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not described
Allocation concealment? Unclear risk Not described
Blinding?
All outcomes
Low risk Identical placebo
Incomplete outcome data addressed?
All outcomes
Unclear risk 26% attrition not included in final analysis
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Dowell 1998 Review article on use of antibiotics for cough, pharyngitis and the common cold
Field 1966 Double blind RCT of ampicillin versus placebo in infants with cough and expiratory wheeze (bronchiolitis).
Excluded from review as all patients had wheeze - an exclusion criteria in our patients
Fiocchi 1988 RCT of Domiodol versus placebo in children. Excluded as domiodol is a mucolytic not antibiotic
Friis 1984 Open randomised prospective trial of antibiotic versus control group in children with pneumonia. All had been
unwell for < 1 week. Excluded as acute cough not chronic
Nevihostenyi 1980 Non RCT. Study of 129 children aged 2 - 8 years who underwent endoscopy for investigation of chronic
bronchitis
O’Brien 1998 Review article on the investigation and treatment of (including use of antibiotics) in children with acute,
subacute and chronic cough
Schaad 1986 Double blind RCT of bacterial lysate vs placebo in acute infections respiratory system therefore excluded as
not antibiotic and not chronic infections
Shann 1985 Non RCT. Review article on treatment of pneumonia.
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(Continued)
Stott 1976 RCT of doxycycline versus placebo in adults with acute cough of <= 1 weeks duration. Excluded as adults and
acute cough
Taylor 1977 Double blind RCT of amoxycillin, co-trimoxazle and placebo in children with viral respiratory illnesses. Ex-
cluded as not chronic cough
Wald 1986 Excluded as cough due to acute sinusitis (that is not non-specific cough) and cough not chronic (<30 days).
Double-blind RCT of amoxycillin, amoxycillin-clavulanate potassium and placebo in 171 children aged 2-16
years with persistent nasal discharge and/or cough. Children receiving antibiotic more likely to be cured then
those receiving placebo (p<0.05 at ten days)
Yun 1983 RCT of antibiotics for sinusitis in children presenting with chronic cough. Excluded because no placebo or “no
treatment” control group. The non-antibiotic group was given expectorants and decongestants which is not an
appropriate control/placebo group. There was also no information given on nature of cough, moist or dry. It
did however precisely defined “clinical cure” as no cough on day 14 of treatment. The results did suggest benefit
with antibiotics in keeping with our results with the difference between the antibiotic( treatment event rate
for cure 46%) and expectorant/decongestant group ( control cure rate 14%) which was statistically significant
(p<0.001)
Characteristics of ongoing studies [ordered by study ID]
Marchant
Trial name or title Randomised controlled double-blinded trial of antibiotics in patients with chronic moist cough
Methods
Participants Children aged 6 months - 14 years with chronic (>3 week duration) moist cough.
Exclusion criteria: Clinical or HRCT-proven bronchiectasis, gross neurodevelopmental delay, cystic fibrosis,
known chronic disease such as interstitial lung disease or cardiac disease. Also children who have had antibiotic
therapy in the preceding 2 weeks or who are allergic to penicillin will be excluded
Interventions Randomisation stratified by age <6 years or > 6 years. Allocated blindly to Augmentin Duo Suspension
400mg/5ml or placebo at dose 22.5mg/kg twice daily for 14 days. Enrolled children will complete cough
diary cards for 5 days pre intervention and total of 4 weeks after intervention. Bronchoscopy and lavage will
take place on day 0 in a number of children
Outcomes Primary Outcome: Assessment of cough scores - pre treatment, immediately prior to treatment and at con-
clusion of treatment. Bronchoalveolar lavage results in responders and non-responders will also be compared
including cytology, microbiology and inflammatory markers
Starting date January 2004
Contact information Dr Julie M Marchant
Respiratory Fellow
Dept. of Respiratory Medicine
Royal Children’s Hospital
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Telephone 1: 61 7 36368523
Telephone 2: 61 7 36368111
Facsimile: 61 7 36361958
E-mail: jmarchant@ausdoctors.net
Notes Study continuing but recruitment slow. Results likely available late 2008
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D A T A A N D A N A L Y S E S
Comparison 1. Clinical failure




participants Statistical method Effect size
1 Children not cured or
substantially improved at
follow-up (using ’intention to
treat’ analysis)
2 140 Odds Ratio (M-H, Fixed, 95% CI) 0.13 [0.06, 0.31]
2 Children not cured or
substantially improved at
follow-up (excluding those
known to have B.Pertussis)
2 128 Odds Ratio (M-H, Fixed, 95% CI) 0.13 [0.05, 0.30]
3 Children not cured or
substantially improved at
follow-up (using available data
only)
2 124 Odds Ratio (M-H, Fixed, 95% CI) 0.12 [0.05, 0.29]
Comparison 2. Illness progression




participants Statistical method Effect size
1 Participants with progression of
disease resulting in additional
medical therapy required
2 125 Odds Ratio (M-H, Fixed, 95% CI) 0.10 [0.03, 0.34]
Comparison 3. Adverse events (reaction to medications)




participants Statistical method Effect size
1 Reaction to medications
(vomiting, diarrhoea, rash)
2 128 Odds Ratio (M-H, Fixed, 95% CI) 1.38 [0.31, 6.08]
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Analysis 1.1. Comparison 1 Clinical failure, Outcome 1 Children not cured or substantially improved at
follow-up (using ’intention to treat’ analysis).
Review: Antibiotics for prolonged moist cough in children
Comparison: 1 Clinical failure
Outcome: 1 Children not cured or substantially improved at follow-up (using ’intention to treat’ analysis)
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Darelid 1993 6/41 30/47 75.0 % 0.10 [ 0.03, 0.28 ]
Gottfarb 1994 17/26 23/26 25.0 % 0.25 [ 0.06, 1.05 ]
Total (95% CI) 67 73 100.0 % 0.13 [ 0.06, 0.31 ]
Total events: 23 (Antibiotics), 53 (Placebo)
Heterogeneity: Chi2 = 1.04, df = 1 (P = 0.31); I2 =4%
Test for overall effect: Z = 4.65 (P < 0.00001)
0.01 0.1 1 10 100
Antibiotics better Control better
Analysis 1.2. Comparison 1 Clinical failure, Outcome 2 Children not cured or substantially improved at
follow-up (excluding those known to have B.Pertussis).
Review: Antibiotics for prolonged moist cough in children
Comparison: 1 Clinical failure
Outcome: 2 Children not cured or substantially improved at follow-up (excluding those known to have B.Pertussis)
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Darelid 1993 6/41 30/47 75.7 % 0.10 [ 0.03, 0.28 ]
Gottfarb 1994 11/20 17/20 24.3 % 0.22 [ 0.05, 0.98 ]
Total (95% CI) 61 67 100.0 % 0.13 [ 0.05, 0.30 ]
Total events: 17 (Treatment), 47 (Control)
Heterogeneity: Chi2 = 0.72, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 4.74 (P < 0.00001)
0.01 0.1 1 10 100
Antibiotics better Control better
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Analysis 1.3. Comparison 1 Clinical failure, Outcome 3 Children not cured or substantially improved at
follow-up (using available data only).
Review: Antibiotics for prolonged moist cough in children
Comparison: 1 Clinical failure
Outcome: 3 Children not cured or substantially improved at follow-up (using available data only)
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Darelid 1993 5/40 30/47 76.8 % 0.08 [ 0.03, 0.25 ]
Gottfarb 1994 9/18 15/19 23.2 % 0.27 [ 0.06, 1.12 ]
Total (95% CI) 58 66 100.0 % 0.12 [ 0.05, 0.29 ]
Total events: 14 (Treatment), 45 (Control)
Heterogeneity: Chi2 = 1.65, df = 1 (P = 0.20); I2 =40%
Test for overall effect: Z = 4.75 (P < 0.00001)
0.01 0.1 1 10 100
Antibiotics better Control better
Analysis 2.1. Comparison 2 Illness progression, Outcome 1 Participants with progression of disease
resulting in additional medical therapy required.
Review: Antibiotics for prolonged moist cough in children
Comparison: 2 Illness progression
Outcome: 1 Participants with progression of disease resulting in additional medical therapy required
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Darelid 1993 2/41 21/47 87.1 % 0.06 [ 0.01, 0.29 ]
Gottfarb 1994 1/18 3/19 12.9 % 0.31 [ 0.03, 3.34 ]
Total (95% CI) 59 66 100.0 % 0.10 [ 0.03, 0.34 ]
Total events: 3 (Antibiotics), 24 (Placebo)
Heterogeneity: Chi2 = 1.24, df = 1 (P = 0.26); I2 =20%
Test for overall effect: Z = 3.67 (P = 0.00025)
0.01 0.1 1 10 100
Antibiotics better Control better
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Analysis 3.1. Comparison 3 Adverse events (reaction to medications), Outcome 1 Reaction to medications
(vomiting, diarrhoea, rash).
Review: Antibiotics for prolonged moist cough in children
Comparison: 3 Adverse events (reaction to medications)
Outcome: 1 Reaction to medications (vomiting, diarrhoea, rash)
Study or subgroup Antibiotics Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gottfarb 1994 3/20 3/20 85.0 % 1.00 [ 0.18, 5.67 ]
Darelid 1993 1/41 0/47 15.0 % 3.52 [ 0.14, 88.76 ]
Total (95% CI) 61 67 100.0 % 1.38 [ 0.31, 6.08 ]
Total events: 4 (Antibiotics), 3 (Control)
Heterogeneity: Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.67)
0.1 0.2 0.5 1 2 5 10
Antibiotics better Control better
A P P E N D I C E S
Appendix 1. Database search strategies
CENTRAL search strategy
#1 MeSH descriptor Cough explode all trees
#2 MeSH descriptor Bronchitis explode all trees
#3 cough* or bronchiti*
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Anti-Bacterial Agents explode all trees
#6 antibiot* or anti-biot* or antimicrob* or anti-microb* or antibacterial* or anti-bacterial* or erythromycin or amoxycillin or ampicillin
or doxycycline
#7 (#5 OR #6)
#8 MeSH descriptor Child explode all trees
#9 MeSH descriptor Infant explode all trees
#10 MeSH descriptor Adolescent explode all trees
#11 MeSH descriptor Pediatrics explode all trees
#12 child* or paediat* or pediat* or adolesc* or infan* or toddler* or bab* or young* or preschool* or pre school* or pre-school* or
newborn* or new born* or new-born* or neo-nat* or neonat*
#13 (#8 OR #9 OR #10 OR #11 OR #12)
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3. (cough$ or bronchit$).mp.
4. 1 or 2 or 3
5. exp Anti-Bacterial Agents/
6. (antibiot$ or anti-biot$ or antimicrob$ or anti-microb$ or antibacterial$ or anti-bacterial$ or erythromycin or amoxycillin or
ampicillin or doxycycline).mp.
7. 5 or 6
8. exp adolescent/ or exp child/ or exp infant/
9. exp Pediatrics/
10. (child$ or paediat$ or pediat$ or adolesc$ or infan$ or toddler$ or bab$ or young$ or preschool$ or pre school$ or pre-school$ or
newborn$ or new born$ or new-born$ or neo-nat$ or neonat$).mp.
11. 8 or 9 or 10
12. 4 and 7 and 11
RCT filter
1. (clinical trial or controlled clinical trial or randomised controlled trial).pt.









11. 9 not (9 and 10)





3. (cough$ or bronchit$).mp.
4. 1 or 2 or 3
5. exp Antibiotic Agent/
6. (antibiot$ or anti-biot$ or antimicrob$ or anti-microb$ or antibacterial$ or anti-bacterial$ or erythromycin or amoxycillin or
ampicillin or doxycycline).mp.





12. (child$ or paediat$ or pediat$ or adolesc$ or infan$ or toddler$ or bab$ or young$ or preschool$ or pre school$ or pre-school$ or
newborn$ or new born$ or new-born$ or neo-nat$ or neonat$).mp.
13. or/8-12
14. 4 and 7 and 13
RCT filter
1. Randomized Controlled Trial/
2. Controlled Study/
3. randomisation/
4. Double Blind Procedure/




9. exp prospective study/
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10. or/1-9
11. (clinica$ adj3 trial$).mp.




16. (latin adj3 square$).mp.
17. exp Comparative Study/
18. ((control$ or prospectiv$ or volunteer$) adj3 (trial$ or method$ or stud$)).mp.
19. (crossover$ or cross-over$).mp.
20. or/11-19




25. 22 or 23
26. 25 not 24
27. 21 not 26
Appendix 2. Search history





WH A T ’ S N E W
Last assessed as up-to-date: 7 October 2010.
Date Event Description
8 October 2010 New search has been performed New literature search run, no new studies found.
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H I S T O R Y
Protocol first published: Issue 2, 2004
Review first published: Issue 4, 2005
Date Event Description
8 April 2008 Amended Updated with searches until 19 March 2008; no new studies
were eligible
6 July 2005 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
For the protocol: Protocol was written by JM and AC, based on previous protocols on cough in children. PM and JG reviewed protocol.
For the review: JM: selection of articles from search, data extraction, data analysis and writing of review. AC: review of articles for
inclusion, data extraction, double data entry, data analysis, writing of review. JG: selection of articles from search. PM: reviewed written
review.
D E C L A R A T I O N S O F I N T E R E S T
Two of the authors (JM and AC) are investigators in an RCT of antibiotics for prolonged moist cough in children. This trial is currently
in progress.
S O U R C E S O F S U P P O R T
Internal sources
• Royal Children’s Hospital Foundation, Brisbane, Australia.
External sources
• Australian Cochrane Airways Group Scholarship 2004, Australia.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
October 2004: During the review process the selection criteria was changed from RCTs comparing antibiotics to placebo medication
to also include studies comparing antibiotics with a ’no treatment’ control group. This was done because there were an insufficient
number of placebo-controlled trials to be sure that the information obtained from unblinded studies would not be clinically useful.
The inclusion criteria were changed to allow studies of children who had prolonged moist cough for >10 days. We planned to assess
the impact of antibiotics on children with prolonged moist cough >3 weeks (our preferred definition of chronic cough) as an a priori
subgroup analysis. We also decided to include studies that were not exclusively limited to children with “moist sounding” cough if
subgroup data were not available and >50% of children had a moist cough or other clinical features consistent with diagnosis (e.g.
sputum production, excess secretions etc). The review uses a summary weighted odds ratio rather than relative risk as was stated in the
protocol. This decision was made as it appeared the most clinically relevant analysis method particularly when converted to number
needed to treat.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
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